SynCardia Introduction: Patrick N.J. Schnegelsberg - Leading the Future of Total Artificial Heart скачать в хорошем качестве

SynCardia Introduction: Patrick N.J. Schnegelsberg - Leading the Future of Total Artificial Heart

SynCardia Total Artificial Heart Introduction CEO, Patrick N.J. Schnegelsberg Welcome to the introduction for Picard Medical, Inc. (Proposed NYSE American Ticker: PMI), parent company of SynCardia Systems, LLC – a global leader in total artificial heart technology, preparing to go public on the NYSE soon. Join CEO Patrick N.J. Schnegelsberg for an overview of its groundbreaking innovations, market position, and growth strategy. Key Highlights: Market Leader: SynCardia is a pioneer in total artificial heart (TAH) technology, serving as a wholly owned subsidiary of Picard Medical, Inc. Only FDA-Approved TAH: The SynCardia Total Artificial Heart (STAH) is the only commercially available TAH approved by the FDA and Health Canada. Global Impact: Over 2,100 implants have been performed in hospitals across 27 countries. Life-Saving Innovation: The STAH replaces both heart ventricles and all four valves, delivering immediate and complete cardiac output for patients facing imminent biventricular failure. Scalable Business Model: SynCardia is well positioned for expansion through a blend of direct sales, distributor partnerships, and comprehensive clinical and technical support. For more details on SynCardia's technology and path forward, visit: https://www.syncardia.com/